Technical Analysis for NVSEF - Novartis Ag Basl

Grade Last Price % Change Price Change
A 87.0 0.55% 0.4800
NVSEF closed up 0.55 percent on Tuesday, May 17, 2022, on 0 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Flat Flat Up

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Cup with Handle Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Up Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.55%
Pocket Pivot Bullish Swing Setup 0.55%
Narrow Range Bar Range Contraction 0.55%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High 6 days ago
Possible Pocket Pivot 6 days ago
Up 1 ATR 6 days ago
Up 1% 6 days ago
5x Volume Pace 6 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Novartis Ag Basl Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; and Conatus Pharmaceuticals Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Health Healthcare Biotechnology Pharmaceuticals Pain Surgery Pharmaceutical Industry In China Immunology Healthcare Products Healthcare Providers Ophthalmology Dosage Forms Active Pharmaceutical Ingredients Lenses Coma Dermatology Pharmaceutical Ingredients Antibiotic Itching Metabolism A Therapeutic Disposable Products Neuroscience Antibiotics Active Pharmaceutical Ingredient Ophthalmic Active Ingredients Dysfunction Allergies Myer Osage Contact Lens Meli Contact Lenses Dosage Form Glaucoma Ibm Pfizer Retina Surgeries Amgen Berkeley Biosimilar Disposable Product Watson Mge Cona Intraocular Lens Surgical Equipment Hepatology University Of California Medicine Products Novartis Ophthalmic Products Therapeutic Device Allergan Biotechnology Based Products Cataract Diagnostic Devices Eye Drop Hormonal Therapy Ocular Itching

Is NVSEF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 95.0
52 Week Low 78.7825
Average Volume 43,123
200-Day Moving Average 86.5726
50-Day Moving Average 86.8378
20-Day Moving Average 88.1705
10-Day Moving Average 86.0510
Average True Range 1.0115
RSI 48.19
ADX 26.37
+DI 40.4012
-DI 54.3841
Chandelier Exit (Long, 3 ATRs) 90.5405
Chandelier Exit (Short, 3 ATRs) 84.2346
Upper Bollinger Bands 93.0728
Lower Bollinger Band 83.2682
Percent B (%b) 0.38
BandWidth 11.1200
MACD Line -0.6888
MACD Signal Line -0.3253
MACD Histogram -0.3635
Fundamentals Value
Market Cap 197.88 Billion
Num Shares 2.27 Billion
EPS 3.09
Price-to-Earnings (P/E) Ratio 28.18
Price-to-Sales 4.26
Price-to-Book 3.83
PEG Ratio 2.86
Dividend 3.08
Dividend Yield 3.54%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 87.0000
Resistance 3 (R3) 87.0000 87.0000 87.0000
Resistance 2 (R2) 87.0000 87.0000 87.0000 87.0000
Resistance 1 (R1) 87.0000 87.0000 87.0000 87.0000 87.0000
Pivot Point 87.0000 87.0000 87.0000 87.0000 87.0000
Support 1 (S1) 87.0000 87.0000 87.0000 87.0000 87.0000
Support 2 (S2) 87.0000 87.0000 87.0000 87.0000
Support 3 (S3) 87.0000 87.0000 87.0000
Support 4 (S4) 87.0000